Ongoing clinical trials will be essential to elucidate the role of Gal-3 in cardio–renal interactions, particularly within systemic conditions such as diabetes, and to assess its potential as a biomarker and therapeutic target in managing combined cardiac and renal impairment. Here, LGALS3 is linked to diabetes mellitus.